GB9816935D0 - Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders - Google Patents

Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders

Info

Publication number
GB9816935D0
GB9816935D0 GBGB9816935.2A GB9816935A GB9816935D0 GB 9816935 D0 GB9816935 D0 GB 9816935D0 GB 9816935 A GB9816935 A GB 9816935A GB 9816935 D0 GB9816935 D0 GB 9816935D0
Authority
GB
United Kingdom
Prior art keywords
thyroid receptor
novel
receptor ligands
glucocortoid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9816935.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio AB filed Critical Karo Bio AB
Priority to GBGB9816935.2A priority Critical patent/GB9816935D0/en
Publication of GB9816935D0 publication Critical patent/GB9816935D0/en
Priority to BR9912742-3A priority patent/BR9912742A/pt
Priority to PCT/IB1999/001447 priority patent/WO2000007972A1/en
Priority to CN99809310A priority patent/CN1311767A/zh
Priority to IL14110699A priority patent/IL141106A0/xx
Priority to DK99936913T priority patent/DK1102739T3/da
Priority to JP2000563607A priority patent/JP2002522407A/ja
Priority to AT99936913T priority patent/ATE238267T1/de
Priority to TR2001/00274T priority patent/TR200100274T2/xx
Priority to DE69907210T priority patent/DE69907210T2/de
Priority to ES99936913T priority patent/ES2193730T3/es
Priority to EP99936913A priority patent/EP1102739B1/en
Priority to CA002339194A priority patent/CA2339194A1/en
Priority to SI9920064A priority patent/SI20579A/sl
Priority to US09/744,865 priority patent/US6492424B1/en
Priority to HU0103222A priority patent/HUP0103222A3/hu
Priority to PL99345824A priority patent/PL345824A1/xx
Priority to IDW20010257A priority patent/ID28805A/id
Priority to SK94-2001A priority patent/SK942001A3/sk
Priority to MXPA01001047A priority patent/MXPA01001047A/es
Priority to KR1020017001279A priority patent/KR20010072113A/ko
Priority to AU51881/99A priority patent/AU753376B2/en
Priority to SE99936913T priority patent/SE1102739T5/xx
Priority to ZA200100832A priority patent/ZA200100832B/xx
Priority to BG105214A priority patent/BG105214A/xx
Priority to NO20010610A priority patent/NO20010610L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9816935.2A 1998-08-05 1998-08-05 Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders Ceased GB9816935D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB9816935.2A GB9816935D0 (en) 1998-08-05 1998-08-05 Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
SE99936913T SE1102739T5 (cg-RX-API-DMAC7.html) 1998-08-05 1999-08-04
CA002339194A CA2339194A1 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
US09/744,865 US6492424B1 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
CN99809310A CN1311767A (zh) 1998-08-05 1999-08-04 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体
IL14110699A IL141106A0 (en) 1998-08-05 1999-08-04 Phenoxyphenyl derivatives and pharmaceutical compositions containing the same
DK99936913T DK1102739T3 (da) 1998-08-05 1999-08-04 Glucocorticoid- og thyroidhormonreceptorligander til behandling af metaboliske lidelser
JP2000563607A JP2002522407A (ja) 1998-08-05 1999-08-04 代謝障害の治療のためのグルココルチコイドおよび甲状腺ホルモン受容体リガンド
AT99936913T ATE238267T1 (de) 1998-08-05 1999-08-04 Glucocorticoid- und thyroidhormonrezeptor- liganden zur behandlung von stoffwechselkrankheiten
TR2001/00274T TR200100274T2 (tr) 1998-08-05 1999-08-04 Metabolik bozuklukların tedavisi için glikokortikoit ve tiroit hormon reseptörü ligandları.
DE69907210T DE69907210T2 (de) 1998-08-05 1999-08-04 Glucocorticoid- und thyroidhormonrezeptor-liganden zur behandlung von stoffwechselkrankheiten
ES99936913T ES2193730T3 (es) 1998-08-05 1999-08-04 Ligandos de receptores de la hormona tiroidea y de glucocortioides para el tratamiento de desordenes metabolicos.
EP99936913A EP1102739B1 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
BR9912742-3A BR9912742A (pt) 1998-08-05 1999-08-04 Ligandos receptores de hormÈnios tireodianos e glicocorticóides para o tratamento de distúrbios metabólicos
SI9920064A SI20579A (sl) 1998-08-05 1999-08-04 Glukokortikoidni in tiroidni hormonski receptorski ligandi za zdravljenje metaboličnih motenj
PCT/IB1999/001447 WO2000007972A1 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
HU0103222A HUP0103222A3 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
PL99345824A PL345824A1 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
IDW20010257A ID28805A (id) 1998-08-05 1999-08-04 Ligand-ligand penerima hormon thyroid dan glucocorticoid untuk menanggulangi gangguan-gangguan metabolik
SK94-2001A SK942001A3 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
MXPA01001047A MXPA01001047A (es) 1998-08-05 1999-08-04 Ligandos receptores de glucocorticoide y hormona de tiroides para el tratamiento de desordenes metabolicos.
KR1020017001279A KR20010072113A (ko) 1998-08-05 1999-08-04 대사 장애를 치료하기 위한 글루코코르티코이드 및티로이드 호르몬 수용체 리간드
AU51881/99A AU753376B2 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
ZA200100832A ZA200100832B (en) 1998-08-05 2001-01-30 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders.
BG105214A BG105214A (en) 1998-08-05 2001-02-02 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
NO20010610A NO20010610L (no) 1998-08-05 2001-02-05 Glukokorticoid- og thyroidhormonreseptorligander for behandling av metabolske lidelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9816935.2A GB9816935D0 (en) 1998-08-05 1998-08-05 Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
GB9816935D0 true GB9816935D0 (en) 1998-09-30

Family

ID=10836671

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9816935.2A Ceased GB9816935D0 (en) 1998-08-05 1998-08-05 Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders

Country Status (26)

Country Link
US (1) US6492424B1 (cg-RX-API-DMAC7.html)
EP (1) EP1102739B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002522407A (cg-RX-API-DMAC7.html)
KR (1) KR20010072113A (cg-RX-API-DMAC7.html)
CN (1) CN1311767A (cg-RX-API-DMAC7.html)
AT (1) ATE238267T1 (cg-RX-API-DMAC7.html)
AU (1) AU753376B2 (cg-RX-API-DMAC7.html)
BG (1) BG105214A (cg-RX-API-DMAC7.html)
BR (1) BR9912742A (cg-RX-API-DMAC7.html)
CA (1) CA2339194A1 (cg-RX-API-DMAC7.html)
DE (1) DE69907210T2 (cg-RX-API-DMAC7.html)
DK (1) DK1102739T3 (cg-RX-API-DMAC7.html)
ES (1) ES2193730T3 (cg-RX-API-DMAC7.html)
GB (1) GB9816935D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0103222A3 (cg-RX-API-DMAC7.html)
ID (1) ID28805A (cg-RX-API-DMAC7.html)
IL (1) IL141106A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01001047A (cg-RX-API-DMAC7.html)
NO (1) NO20010610L (cg-RX-API-DMAC7.html)
PL (1) PL345824A1 (cg-RX-API-DMAC7.html)
SE (1) SE1102739T5 (cg-RX-API-DMAC7.html)
SI (1) SI20579A (cg-RX-API-DMAC7.html)
SK (1) SK942001A3 (cg-RX-API-DMAC7.html)
TR (1) TR200100274T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000007972A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200100832B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051971A1 (en) 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
GB9928805D0 (en) * 1999-12-07 2000-02-02 Karobio Ab Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
GB0029102D0 (en) 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
GB0029100D0 (en) * 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
GB0111861D0 (en) 2001-05-15 2001-07-04 Karobio Ab Novel compounds
KR20040027927A (ko) 2001-08-24 2004-04-01 카로 바이오 아베 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근
GB0120691D0 (en) * 2001-08-24 2001-10-17 Karobio Ab Novel Compounds
DE60208132T2 (de) 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolcaroboxylsäure als Thyroidrezeptor-Liganden
WO2003026632A2 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
GB0215978D0 (en) * 2002-07-10 2002-08-21 Karobio Ab Novel compounds
AU2002951977A0 (en) 2002-10-10 2002-10-24 Leo Engineering Pty Ltd Improvements to two-part vessels
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
WO2009129225A1 (en) * 2008-04-15 2009-10-22 Osteogenex, Inc. Compounds and methods for altering bone growth
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
WO1999063976A2 (en) * 1998-06-08 1999-12-16 Karo Bio Ab Liver-selective glucocorticoid antagonist for treating diabetes

Also Published As

Publication number Publication date
WO2000007972A1 (en) 2000-02-17
SE1102739T5 (cg-RX-API-DMAC7.html) 2003-09-16
SK942001A3 (en) 2001-12-03
AU753376B2 (en) 2002-10-17
ZA200100832B (en) 2001-10-31
KR20010072113A (ko) 2001-07-31
HUP0103222A3 (en) 2002-12-28
NO20010610D0 (no) 2001-02-05
EP1102739A1 (en) 2001-05-30
DE69907210T2 (de) 2004-02-19
BR9912742A (pt) 2001-05-02
AU5188199A (en) 2000-02-28
JP2002522407A (ja) 2002-07-23
CN1311767A (zh) 2001-09-05
ID28805A (id) 2001-07-05
IL141106A0 (en) 2002-02-10
ES2193730T3 (es) 2003-11-01
TR200100274T2 (tr) 2001-09-21
ATE238267T1 (de) 2003-05-15
EP1102739B1 (en) 2003-04-23
US6492424B1 (en) 2002-12-10
SE1102739T3 (cg-RX-API-DMAC7.html) 2003-08-12
HUP0103222A2 (hu) 2002-01-28
CA2339194A1 (en) 2000-02-17
DE69907210D1 (de) 2003-05-28
PL345824A1 (en) 2002-01-14
MXPA01001047A (es) 2002-09-02
NO20010610L (no) 2001-04-04
SI20579A (sl) 2001-12-31
DK1102739T3 (da) 2003-08-18
BG105214A (en) 2001-12-29

Similar Documents

Publication Publication Date Title
ZA200100832B (en) Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders.
CA2294098A1 (en) Novel thyroid receptor ligands and method
NZ512422A (en) Novel thyroid receptor ligands and method II
ATE196252T1 (de) Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin
CZ85395A3 (en) Derivatives of vaprooic and 1-valproenic acids and pharmaceutical preparations based thereon
ZA949246B (en) Use of,and method of treatment using , hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation.
MY119350A (en) Propiophenone derivatives and process for preparing the same
MY140525A (en) Pharmaceutical uses for alpha2delta ligands
NZ330216A (en) Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis
FR2697252B1 (fr) Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
AU2251901A (en) Methods and compounds for inhibiting MRP1
Stoeckel et al. Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability
AU2293588A (en) New androstane 17-carboxylic acid ester, process for their preparation and drugs containing them
WO2004066929A3 (en) Cycloalkyl containing anilide ligands for the thyroid receptor
CA2053820A1 (en) Method of Inhibiting Metabolism of Cholesterol
HUT64309A (en) Process for production pharmaceutical preparations having benzazepine compounds as effective substance and the new effective substance
Dhar et al. Approaches to short-acting neuromuscular blocking agents: Nonsymmetrical bis-tetrahydroisoquinolinium mono-and diesters
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
AU2224795A (en) Ameliorant or remedy for paraneoplastic syndrome
EP0217271A2 (en) Amide derivatives and 5-lypoxygenase inhibitors containing the same
JPS6481A (en) H2-receptor antagonist compound
TW290536B (en) The derivatives and the prepared method of 2,2-dimethyl-5-substituted phenoxy-pentanoic acids

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)